Third Pole Therapeutics develops tankless, on-demand inhaled nitric oxide (iNO) systems, including the portable hospital eNOcare™ and the miniaturized wearable eNOfit™. Its platform generates iNO by combining electricity and ambient air, creating a "make it and take it" therapy that avoids compressed gas cylinders. The company is targeting a 2023 FDA submission for eNOcare™ to enter the existing $600 million iNO hospital market. eNOfit™ is scheduled to enter clinical trials in the next few months and the company estimates its commercial opportunity exceeds $12B annually. Third Pole has received development support from NIH awards and has raised Series B commitments to date of over $85M following a $32M strategic equity investment. The strategic investor is described as a large medical device innovator and the funding is intended to accelerate final development and regulatory readiness.

Total raised

$32M

Funding rounds

1

Latest round

Series B

Latest activity

Dec 2022